Chairman of the Board
Ph.D. Juris Hmelnickis
Member of the Board
Quality and R&D Director / Member of the Board
Jere Tapani Niemi
Business Development Director
JSC Kalceks starts production and commercialization of Hydromorphone Kalceks 2, 10, 20 and 50 mg/ml solution for injections/infusions. Product has been registered via decentralized registration procedure involving 10 European Union countries. First sales are expected in Germany and Netherlands following by other EU countries. Hydromorphone Kalceks 2, 10, 20 and 50 mg/ml solution for injections/infusions is a third new product that Kalceks launches within this year.
Being responsible for drug and patient safety, JSC «Kalceks» develops adverse drug reaction monitoring (pharmacovigilance) in all countries, where our drugs are available.
«Kalceks» and its mother company «Grindeks» maintains single pharmacovigilance system.
Task of pharmacovigilance division is to eliminate potential risk to patients, and detect of both positive and negative new effects.
Division is guided by Good Pharmacovigilance Practice and national legislation. Received information is verified, evaluated and reported when required.
If using or administering our drugs you notice side effect, lack of efficacy or other unusual reaction, please report it in the way most convenient for you
by email: email@example.com or firstname.lastname@example.org
by post: Pharmacovigilance division, JSC Grindeks, Krustpils street 53, LV-1057, Riga, Latvia
by phone: +371 67083244 (business hours) or +371 22038854 (after business hours)
We guarantee full confidentiality of your data!
We also invite to report about cases of inappropriate drug use!
If you want to report side effects on «Kalceks» drugs, we kindly advise you to use abovementioned options or fill form at homepage of mother company «Grindeks»:
Qualified person for pharmacovigilance
Direct telephone number: +371 22038854